Javascript must be enabled to continue!
Clinical Efficacy of Dexlansoprazole vs Esomeprazole in Gastro-Oesophageal Reflux Disease: A Randomized Clinical Trial.
View through CrossRef
Background: Gastro-Esophageal reflux disease (GERD) is a very common problem in a gastrointestinal clinical setting. Still, the best treatment for it remains debatable as there are many new drugs that have evolved for its treatment in addition to dietary modification.Objective: To compare the clinical efficacy of Dexlansoprazole (modified-release 60 mg) and esomeprazole (40 mg) for the resolution of symptoms of GERD.Material and Methods: This randomized controlled trial or intervention was conducted for comparing the clinical efficacy of Dexlansoprazolevs Esomeprazole for the symptomatic treatment of GERD.A total of 100 endoscopically diagnosed patients were selected and were randomly allocated to two groups each containing 50 patients. Group 'A' contained 50 patients who were given 60 mg Dexlansoprazole for 2 weeks and group 'B' also contained the same number of patients receiving the treatment with Esomeprazole 40 mg for the same duration.After informed consent, a validated tool FSSG (Frequency Scale for the Symptoms of GERD) was used to collect the responses of patients. The Chi-square test was used to compare the responses of two groups considering a P-value of <0.05 as significant.Results: Among domains of frequency scale for the symptoms of GERD, only dysphagia was significantly better in Dexlansoprazole group, P-valueof< 0.05 while rest of the symptoms were statistically same with a p-value of > 0.05.Conclusion: This study concluded that the symptomatic relief of GERD after 2 weeks of therapy with Esomeprazole and Dexlansoprazole was the same except for dysphagia.Keywords: Dexlansoprazole, Esomeprazole,Gastroesophageal reflux disease.
Title: Clinical Efficacy of Dexlansoprazole vs Esomeprazole in Gastro-Oesophageal Reflux Disease: A Randomized Clinical Trial.
Description:
Background: Gastro-Esophageal reflux disease (GERD) is a very common problem in a gastrointestinal clinical setting.
Still, the best treatment for it remains debatable as there are many new drugs that have evolved for its treatment in addition to dietary modification.
Objective: To compare the clinical efficacy of Dexlansoprazole (modified-release 60 mg) and esomeprazole (40 mg) for the resolution of symptoms of GERD.
Material and Methods: This randomized controlled trial or intervention was conducted for comparing the clinical efficacy of Dexlansoprazolevs Esomeprazole for the symptomatic treatment of GERD.
A total of 100 endoscopically diagnosed patients were selected and were randomly allocated to two groups each containing 50 patients.
Group 'A' contained 50 patients who were given 60 mg Dexlansoprazole for 2 weeks and group 'B' also contained the same number of patients receiving the treatment with Esomeprazole 40 mg for the same duration.
After informed consent, a validated tool FSSG (Frequency Scale for the Symptoms of GERD) was used to collect the responses of patients.
The Chi-square test was used to compare the responses of two groups considering a P-value of <0.
05 as significant.
Results: Among domains of frequency scale for the symptoms of GERD, only dysphagia was significantly better in Dexlansoprazole group, P-valueof< 0.
05 while rest of the symptoms were statistically same with a p-value of > 0.
05.
Conclusion: This study concluded that the symptomatic relief of GERD after 2 weeks of therapy with Esomeprazole and Dexlansoprazole was the same except for dysphagia.
Keywords: Dexlansoprazole, Esomeprazole,Gastroesophageal reflux disease.
Related Results
Variants of Gastroesophageal Reflux Disease Depending on the Type of Reflux
Variants of Gastroesophageal Reflux Disease Depending on the Type of Reflux
The purpose of the work was to study the clinical course of gastroesophageal reflux disease with acid and alkaline refluxes, to investigate the psychosomatic state, the features of...
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract
Introduction
Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
Impact of gastro-oesophageal reflux on microRNA expression, location and function
Impact of gastro-oesophageal reflux on microRNA expression, location and function
Abstract
Background
Ulceration of the oesophageal squamous mucosa (ulcerative oesophagitis) is a pathological manifestation of gastro-oesophageal...
Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis
Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis
Objectives
Gastro-oesophageal reflux symptoms are common in the community, but there has been no definitive systematic review and meta-analysis of data from all...
Oesophageal atresia: Are “long gap” patients at greater anesthetic risk?
Oesophageal atresia: Are “long gap” patients at greater anesthetic risk?
SummaryBackgroundLong gap oesophageal atresia occurs in approximately 10% of all oesophageal atresia infants and surgical repair is often difficult with significant postoperative c...
Long term survival in gastro-oesophageal cancer: Table 1
Long term survival in gastro-oesophageal cancer: Table 1
Introduction
One of the changes implemented following the publication of the Improving Outcome Guidances (IOG) is the centralisation of cancer services to ensur...
Increased risk of gastro-oesophageal cancers among married couples: Data from the Ardabil Cancer Registry (ACR) in Northwest of Iran, 2002-2016
Increased risk of gastro-oesophageal cancers among married couples: Data from the Ardabil Cancer Registry (ACR) in Northwest of Iran, 2002-2016
Abstract
Background: The study of cancer in spouses may play an important role in the assessment of cancer etiology. This study aims to evaluate the risk of gastro-oesophag...
Treating gastro-oesophageal cancer- a national comparison: Table 1
Treating gastro-oesophageal cancer- a national comparison: Table 1
Introduction
The incidence of gastric cancer is on decline but cases of oesophageal adenocarcinoma and junctional tumour are rising in UK. Patients present at a...

